Literature DB >> 17005408

Extensive extracellular matrix depositions in active multiple sclerosis lesions.

Jack van Horssen1, Lars Bö, Christien D Dijkstra, Helga E de Vries.   

Abstract

In the central nervous system, basement membrane (BM) constituents are predominantly associated with the vasculature. However, under inflammatory conditions, the expression of BM components may alter. Here, we investigated the distribution of several BM components, including laminin, collagen type IV and heparan sulfate proteoglycans in various multiple sclerosis (MS) lesions. We observed irregular and discontinuous BMs in active lesions. Throughout active MS lesions, we found dense networks of BM proteins, which were surprisingly not associated with the cerebrovasculature. These striking parenchymal networks were not observed in chronic inactive MS lesions and brains of non-neurological controls. In addition, we studied the distribution of transforming growth factor-beta1 (TGF-beta1), since it is known as a major modulator of ECM production. Leukocytes, in particular CD68-positive macrophages, expressed high levels of TGF-beta1 and were located in close proximity to parenchymal BM deposits in the MS lesions. We postulate that these BM networks may play a role in the further recruitment of inflammatory cells and form a barrier for axonal regeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005408     DOI: 10.1016/j.nbd.2006.08.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  46 in total

Review 1.  Pathophysiology of the brain extracellular matrix: a new target for remyelination.

Authors:  Lorraine W Lau; Rowena Cua; Michael B Keough; Sarah Haylock-Jacobs; V Wee Yong
Journal:  Nat Rev Neurosci       Date:  2013-08-29       Impact factor: 34.870

2.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

3.  Differential Regulation of MeCP2 Phosphorylation by Laminin in Oligodendrocytes.

Authors:  Zalak S Parikh; Ashutosh Tripathi; Prakash P Pillai
Journal:  J Mol Neurosci       Date:  2017-06-14       Impact factor: 3.444

4.  Brain-specific deletion of extracellular signal-regulated kinase 2 mitogen-activated protein kinase leads to aberrant cortical collagen deposition.

Authors:  Daniel S Heffron; Gary E Landreth; Ivy S Samuels; James W Mandell
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 5.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

6.  Transforming growth factor beta1 gene variation Leu10Pro affects secretion and function in hepatic cells.

Authors:  Xing Gu; Xin Ji; Le-Hua Shi; Chang-Hong Yi; Yun-Peng Zhao; Ai-Hua Wang; Lun-Gen Lu; Wen-Bo Yu; Chun-Fang Gao
Journal:  Dig Dis Sci       Date:  2012-05-22       Impact factor: 3.199

7.  Inhibition of transforming growth factor-β attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage.

Authors:  Anatol Manaenko; Tim Lekic; Margaret Barnhart; Richard Hartman; John H Zhang
Journal:  Stroke       Date:  2014-01-14       Impact factor: 7.914

Review 8.  Brain extracellular matrix in neurodegeneration.

Authors:  Dafna Bonneh-Barkay; Clayton A Wiley
Journal:  Brain Pathol       Date:  2008-07-25       Impact factor: 6.508

9.  Multiple sclerosis susceptibility alleles in African Americans.

Authors:  B A Johnson; J Wang; E M Taylor; S J Caillier; J Herbert; O A Khan; A H Cross; P L De Jager; P-A F Gourraud; B C A Cree; S L Hauser; J R Oksenberg
Journal:  Genes Immun       Date:  2009-10-29       Impact factor: 2.676

10.  Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.

Authors:  M S Freedman; J Laks; N Dotan; R T Altstock; A Dukler; C J M Sindic
Journal:  Mult Scler       Date:  2009-04       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.